Navigation Links
Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1

OKLAHOMA CITY, May 4, 2011 /PRNewswire/ -- Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.  

The placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose study of SelG1 will enroll approximately 30 healthy subjects. This study will evaluate the safety and pharmacology of SelG1 prior to advancement into a Phase II trial in patients with sickle cell disease.

"This Phase I study represents the first step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and we are excited to initiate the clinical development of this novel compound," said Dr. Scott Rollins, Selexys President and CEO. "This Phase I trial represents a key milestone for Selexys as we transition from a preclinical to a clinical development stage biopharmaceutical company."

In 2008, Selexys received orphan-drug designation for SelG1 from the Food and Drug Administration Office of Orphan Products Development for the treatment of vasoocclusive crisis, a severe and painful complication of sickle cell disease. Orphan drug designation is awarded to therapeutics with the potential for safe and effective treatment diagnosis or prevention of rare diseases and disorders that affect fewer than 200,000 people.

About SelG1

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. In preclinical studies, inhibition of P-selectin has been shown to effectively prevent vasoocclusion by blocking critical cell-cell interactions that drive this process. Therapeutic blockade of P-selectin may therefore reduce vasoocclusion and subsequent crises in patients with sickle cell disease.

"SelG1 represents a first-in-class therapeutic approach for the treatment of sickle cell disease and potentially other proinflammatory and prothrombotic conditions," stated Dr. Russell Rother, who heads the clinical development program for Selexys. "Effective therapies that target vasoocclusion are needed to address the serious complications in patients with this life-threatening disease."

The SelG1 program for sickle cell disease is supported by a Small Business Innovation Research (SBIR) fast-track award #5R44HL093893-02 through the National Heart, Lung and Blood Institute.

About Selexys Pharmaceuticals

Selexys is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation and thrombosis across a broad range of severe diseases. Selexys is also developing SelK1, a fully human monoclonal antibody directed against PSGL-1 for the treatment of Crohn's Disease and other inflammatory disorders. Selexys is headquartered in Oklahoma City, OK.  For additional information please visit our website at  

SOURCE Selexys Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aires Pharmaceuticals Appoints Edwin L. Parsley as Chief Medical Officer
2. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
3. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
8. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
9. Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill Lynch Health Care Conference
Post Your Comments:
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):